Rhizen Pharmaceuticals Sa

Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Tg Therapeutics, Inc.

Rhizen Pharmaceuticals Na

Incozen Therapeutics Pvt. Ltd.

Swaroop K V S Vakkalanka

Srikant Viswanadha

Govindarajulu Babu

Prashant Kashinath Bhavar

Dhanapalan Nagarathnam

Meyyappan Muthuppalaniappan

Peter Sportelli

Michael S Weiss

Hari P Miskin

Prashant K Bhavar

The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.

3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases

This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid.

Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid

Highly effective combinations of a compound of formula A (a PI3K&#x3b4; selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K&#x3b4; and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases

The present invention relates to dual delta (&#x3b4;) and gamma (&#x3b3;) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

Dual selective PI3 delta and gamma kinase inhibitors

Highly effective combinations of a compound of formula A (a PI3K&#x3b4; selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K&#x3b4; and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Growing community of inventors

La Chaux-de-Fonds, Switzerland

Swaroop K V S Vakkalanka